Glycomic Therapeutics Market is expected to reach US$ 257,578.79 Million by 2028

Synthetic Segment to Account for Largest Share in Glycomic Therapeutics Market during 2022–2028

According to our new research study on "Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Class, Structure, Indication, and Mode of Action," the market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million by 2028; it is estimated to grow at a CAGR of 15.8% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market. The wide application areas of glycan-based drugs, followed by the development of new treatment processes and increasing research & development in the field of glycomic therapeutics, are the key drivers propelling the market growth. However, the shortage of skilled professionals and lack of research & development laboratories in developing countries is hampering the overall market growth.

Based on class, the glycomic therapeutics market is bifurcated into isolated and synthetic. In 2021, the synthetic segment accounted for a larger market share. However, the isolated segment is expected to register a higher CAGR of 16.3% during the forecast period. The major driving factors for the growth of the synthetic segment are developing structures in molecular biology, protein engineering, and diagnostics and increasing research activities in the life science industry.

Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2021. However, the targeting sialic acid segment is anticipated to register the highest CAGR during the forecast period.

Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher’s diseases, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others. The influenza type A & B segment held the largest market share in 2021, and it is expected to continue a similar trend during the forecast period.

Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others. In 2021, the erythropoietin & enzyme replacement therapy (ERT) segment held the largest share of the market. However, the inhibits neuraminidase segment is expected to register the highest CAGR during the forecast period.

The onset of the COVID-19 pandemic positively impacted the glycomic therapeutics market. Pharmaceutical and biotechnology companies invested a huge amount in producing several pipeline products that can effectively combat the spread of SARS-CoV-2. Moreover, during the pandemic, the demand for the development of new drugs and vaccines increased to tackle COVID-19 in patients suffering from several other diseases. The increased number of researches led to high utilization of technology instead of human resource to prevent the spread of SARS-CoV-2. Furthermore, governments of Asia Pacific countries organized programs and open challenge events for researchers to develop innovative drugs for the treatment of COVID-19. Such events increased the overall number of research on COVID-19 owing to increased government funding.

Based on region, the glycomic therapeutics market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In North America, the US held the largest market share in 2021. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Growing healthcare infrastructure and evolving pharmaceutical and biopharmaceutical industries have provided immense growth to the glycomic therapeutics market in the Asia Pacific region. In addition, increasing participation by contract research organizations (CROs) in the development and production of drugs is expected to influence the overall growth of the glycomic therapeutics market during the forecast period.

Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are among the leading companies operating in the glycomic therapeutics market.  

Glycomic Therapeutics Market, by Region, 2021

By geography, the global glycomic therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com